Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
The main purpose of this study is to learn about the safety and tolerability of an experimental drug, Venetoclax, when it is given along with Decitabine in subjects diagnosed with acute myeloid leukemia (AML).
Acute Myeloid Leukemia
DRUG: Decitabine|DRUG: Venetoclax
The rate of dose limiting toxicity (DLT), Determine the rate of subjects who experience a dose limiting toxicity and the maximum tolerable dose, 24 months
Levels of toxicity with combination regimen, Levels of toxicity experienced with the combination regimen will be reported using data summaries of adverse events, dose limiting toxicity and other safety parameters., 24 months|Assessment of Overall Survival, Survival will be measured in months from the date of subject enrollment to the date of death., 24 months
The main purpose of this study is to learn about the safety and tolerability of an experimental drug, Venetoclax, when it is given along with Decitabine in subjects diagnosed with acute myeloid leukemia (AML).